Entries by admin

Flagellin-induces a hypersecretory phenotype in primary human bronchial epithelial cells, presented at North America Cystic Fibrosis Conference, Orlando, October 2016

/in /by

The TLR5-agonist flagellin (FLG) is the key protein component of bacterial flagella expressed by a number of organisms including Pseudomonas aeruginosa. The proinflammatory activity of bacterial FLG has been well documented in leukocytes although the effects on airway epithelial function are less clear. More information

Pharmacological characterisation of TMEM16A regulators, presented at The 13th European Cystic Fibrosis Basic Science Conference, Pisa, Italy, March 2016

/in /by

TMEM16A was recently identified as a calcium-activated chloride conductance and a key orchestrator of anion secretion in the human airway epithelium (Caputo et al 2008; Schroeder et al 2008; Yang et al 2008). It is now clinically established that promoting anion secretion in the airway leads to enhanced mucus clearance and reduced exacerbation frequency in […]

Flagellin-induces a hypersecretory phenotype in primary human bronchial epithelial cells, presented at The 13th European Cystic Fibrosis Basic Science Conference, Pisa, Italy, March 2016

/in /by

A screen of microbial-derived products using a 3D model of the human airway epithelium (bronchospheres) revealed flagellin (FLG) as a potential regulator of mucociliary structure and function. Flagellin, a TLR5-agonist, is the key protein component of bacterial flagella expressed by a number of organisms including Pseudomonas aeruginosa. Considering that mucus plugs in the airways of […]

New drug discovery company announces additional funding to tackle chronic respiratory disease

/in /by

Brighton, Sussex, May 20th 2015 – ENTERPRISE THERAPEUTICS Ltd, a drug discovery company focused on new therapeutics for respiratory diseases, today announced that it has secured an additional £2.4m ($3.6m) in Series-A financing. The funds are comprised of £2m by new investor, Imperial Innovations and £0.4m increase by founding investor Epidarex, bringing the total Series-A […]

World class drug discovery team launches new company to tackle chronic respiratory disease

/in /by

Brighton, Sussex, February 12th 2015 – ENTERPRISE THERAPEUTICS Ltd, a drug discovery company focussed on novel therapeutics for respiratory diseases, today announced that it has secured £1.6m ($2.4m) in initial Series-A financing from Epidarex Capital. The proceeds will fund, in parallel, low molecular weight drug discovery and new target identification programs. The company will be […]